FSSAI lens on health supplements

Press Trust of India New Delhi
Last Updated : Jul 24 2015 | 1:31 AM IST
Clamping down on mis-labelling of “health supplements”, food safety regulator FSSAI on Thursday proposed banning the sale of these products as “medicines” and announced new norms for products based on ayurveda, sidhha, unani and other traditional health systems.

Under the new draft regulations, companies can’t claim that their nutraceuticals and health supplement products are for therapeutic and curative purposes.

“Every package of food or health supplements shall carry the words FOOD or HEALTH SUPPLEMENT... the term ‘NOT FOR MEDICINAL USE’ shall be prominently written on the label,” said a draft order issued by FSSAI, which recently created a flutter by banning the popular Maggi noodles.

The Food Safety Standards Authority of India (FSSAI) has also proposed the maximum usage levels for cow’s milk, buffalo’s milk, camel’s milk, ghee, curd, butter, honey, gold, gold foil, silver, pearl in ayurveda, siddha and unani ingredients based products.

The limit has been fixed as maximum usage levels per day for use as a health or food supplements which are based on ayurveda, siddha and unani.

The regulator will finalise the safety norms after receiving comments from all stakeholders on the draft note.

FSSAI said that the benefits of specialty foods containing ingredients based on ayurveda, unani and siddha and other traditional health systems of India, should be shown by science based evidence.

Yesterday, industry body Assocham had released a knowledge paper suggesting that FSSAI should come up with safety norms for nutraceuticals and dietary supplements.

In the paper, the industry body said about 60-70 per cent supplements in the nutraceuticals market, which has potential to grow to USD 12.2 billion in the next five years, are fake and such unregistered and unapproved products should be recalled.

India accounts for 1.5 per cent of the global nutraceuticals market.

Heinz, Kellogg's, Nestle, Hormel, Unilever, Johnson & Johnson and GlaxoSmithKline Pharmaceuticals are key players in this segment.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 24 2015 | 12:29 AM IST

Next Story